

September 17, 2015

3800 Reservoir Rd., NW Washington, DC 20007 202-444-1035 PHONE 202-444-1122 FAX MedStarGeorgetown.org

Scott Rowley, MD, FACP Michele L. Donato, MD, FACP Andrew L. Pecora, MD, FACP, CPE David H. Vesole, MD, PhD, FACP

Chair, Academic Promotions Committee Jagiellonian University

Re: Academic Promotion of Artur Jurczyszyn, MD, PhD

To Whom It May Concern:

It is my extreme pleasure to write a letter of recommendation in support of the academic promotion of Dr. Artur Jurczyszyn to Associate Profressor of Medicine at Jagiellonian University. I have known Dr. Jurczyszyn in excess of 5 years. During these 5+ years, I have developed a growing respect for his intelligence, enthusiasm, compassion, patient management and scientific endeavors. We have worked together in a number of projects leading to manuscripts submitted for publication including studies in central nervous system myeloma, myeloma in pregnancy, the utilization of cyclophosphamide and etoposide for optimal stem cell mobilization, and skin manifestations in myeloma. In addition to his clinical interests, we have also collaborated on a basic science study on MET receptor signaling using siRNA in multiple myeloma cells in vitro and in vivo. Given his clinical responsibilities and competitive resource allocations, his productivity is impressive. To further his expertise in plasma cell dyscrasias, Dr. Jurczyszyn has been a visiting professor under my sponsorship at the John Theurer Cancer Center in Hackensack, NJ. In addition, I have been honored to be an invited guest at three of the four yearly Krakow international plasma cell dyscrasia conferences which has included world renowned faculty organized by Dr. Jurczyszyn.

Dr. Jurczyszyn is well-known in the international multiple myeloma community as he serves as a member of the International Myeloma Working Group-a group of 170 myeloma experts worldwide-and has served on a number of consensus panels. In addition to the joint clinical endeavors cited above, Dr. Jurczyszyn has written extensively in other areas of myeloma biology and treatment including the role of serum free light chain in the diagnosis of monoclonal gammopathies and the role of the bone marrow micro environment in the myeloma pathogenesis. His basic science research has been published in respected journals including Leukemia Research on the plasma fatty acid profile in multiple myeloma. He is a recognized clinical investigator, sought after by pharmaceutical companies for protocol enrollment leading to his being a co-author on important treatment abstracts on new agents for the treatment of multiple myeloma, including, elotuzumab and daratumumab.

Outside of his clinical care and basic science pursuits, Dr. Jurczyszyn is also a teacher and mentor to medical students and medical residents at the Jagiellonian University Medical School. Even though he is early in his own professional career, he provides encouragement and mentorship to others in pursuit of advancing their academic careers.

In collaboration with



I have been awarded academic appointments at a number of established Universities, currently Georgetown University where I am a Professor of Medicine, and I am familiar with the requirements for academic advancement. Based on my review of Dr. Jurczyszyn professional productivity and personal achievements, he would fulfill the criteria for advancement to Associate Professor. I wholeheartedly recommend Dr. Jurczyszyn, without reservation, for advancement to Associate Professor.

Sincerely,

David H. Vesole, MD, PhD

Director, Myeloma Program Member, BMT Division

Professor of Medicine, Georgetown University

Co-Chief, Myeloma Division Director, Myeloma Research John Theurer Cancer Center